This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

This module looks at the safety profile of once-weekly semaglutide 2.4 mg in the STEP clinical trial programme in which semaglutide is under investigation for the management of body weight in people with overweight or obesity. The module includes the incidence of overall side effects, gastrointestinal side effects, gallbladder-related disorders, and malignant neoplasms.

 

At the end of this module, you will be familiar with the safety profile of once-weekly semaglutide 2.4 mg in adults with overweight and obesity in the STEP clinical trials. You will know what the most common side-effects with semaglutide 2.4 mg are and be better equipped to help guide your patient during obesity treatment.